Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3857 The use of quantitative contrast-enhanced endoscopic ultrasound in the evaluation of pancreatic neuroendocrine tumors – Can we move from quality to quantity? A proof-of-concept study

Introduction: Contrast-enhanced EUS (CE-EUS) is a helpful tool for the diagnosis of pancreatic focal lesions, as pancreatic cancer (PC) and pancreatic neuroendocrine tumor (pNEN). The enhancement of the lesion after contrast medium injection is usually assessed qualitatively and arbitrarily by the endosonographer. Dedicated software has recently been developed to obtain an unbiased quantitative assessment using perfusion parameters.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Bina N, Capurso G, Zaccari P, Petrone M,

Keywords: CE-EUS, pNEN, artificial intelligence, pancreatic cancer, prediction,

#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases

Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: sunitinib, everolimus,

#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience

Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: octreotide, lanreotide,

#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)

Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: capecitabine,

#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors

Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ramundo V, Faggiano A, De Stefano G, Marciello F, Marotta V,

Keywords: neuroendocrine tumor, liver metastases, CEUS, prognostic factors, tumor detection,